Clinical trial
A Phase 1 Dose Escalation and Expansion Study of CID-103, an Anti-CD38 Antibody, in Patients With Previously Treated Relapsed or Refractory Multiple Myeloma
NCT04758767 is registered in ClinicalTrials.gov with CASI pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose Escalation and Expansion Study of CID-103, an Anti-CD38 Antibody, in Patients With Previously Treated Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- CASI pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 22, 2021
- Completion date
- January 19, 2023
- Enrollment
- 10 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.